Take the next step with Precise Tumor
Request more information or explore ordering options to bring Precise Tumor testing to your practice.
Take the next step with Precise Tumor
Whether you’ve heard about genetic testing before or want to learn more, we can help provide in-depth information on the test and your testing options.
(800) 469-7423
cscomments@myriad.com
Precise Tumor delivers clarity and actionable answers
Precise Tumor is a next generation sequencing assay that analyzes more than 500 cancer-related genes, as well as key immuno-oncology biomarkers such as microsatellite instability (MSI) and tumor mutational burden (TMB), with broad coverage of guidelines.1
- Quickly determine the next steps for your patients by identifying actionable genomic variants and biomarkers associated with FDA-approved therapies and clinical trials
- Access all the information you need in a clear, concise report with evidence-based prioritization of biomarkers
- Precise Tumor combines DNA and RNA sequencing to detect more fusions and splice variants compared to DNA-only tests2-5
A comprehensive panel delivering actionable insights for multicancer care
Precise Tumor identifies clinically relevant DNA and RNA variants to help guide personalized treatment decisions. By focusing on key guideline-recommended biomarkers and emerging pan-cancer targets, Precise Tumor enables comprehensive and confident treatment planning.
Explore key cancer-specific biomarkers:
How to test with Precise Tumor
Fill out a test request form in the Myriad Genetics provider portal
Fill out a test request form in the Myriad Genetics provider portal
Our laboratory processing staff will contact your pathology partner directly to obtain the tumor sample for Precise Tumor testing
Our laboratory processing staff will contact your pathology partner directly to obtain the tumor sample for Precise Tumor testing
Results will be reported in the provider portal as they become available
Results will be reported in the provider portal as they become available
One simple order. Comprehensive results.
With Myriad Oncology, you can receive comprehensive results for germline testing, tumor genomic profiling, and HRD testing in one single ordering experience, getting clear, fast answers for your patients.
Myriad Oncology empowers you to transform patient care
For a complete approach to cancer risk management and treatment planning, Precise Tumor should be combined with MyRisk and appropriate tumor test to deliver powerful results informing patient care across the entire journey-from assessing hereditary cancer syndromes to guiding treatment decisions.
Combine germline and tumor genomic insights to identify hereditary cancer risks and actionable gene variants, enabling personalized treatment plans and targeted therapies. MyRisk and Precise Tumor focus on clinically relevant variations in the genome, where each test couples RNA analysis with DNA sequencing to provide more refined interpretation of results.
Integrate germline and tumor genomic profiling with HRD testing to identify more patients most likely to benefit from PARP inhibitors. Precise Tumor and MyChoice deliver a powerful combination of actionable tumor genomic information and homologous recombination status, optimizing treatment strategies for ovarian cancers.
For your patients with early-stage breast cancer, pair germline testing with tumor genomic insights and breast cancer recurrence assessment to guide personalized decisions on risk-reducing surgeries and adjuvant therapy strategies.
Myriad Oncology’s portfolio of products delivers:
- Integrated genetic and tumor genomic insights to personalize care for each cancer patient
- Confident risk and recurrence assessments to inform both preventive and therapeutic decisions
- Streamlined reporting to prioritize actionable insights at every step of the cancer journey
What to expect with every Precise Tumor test
Actionable
Precise Tumor simplifies patient care for oncologists by providing straightforward interpretations, prioritization of therapies, and the next steps specific to each patient’s genomic results.
Accurate
Precise Tumor combines DNA and RNA sequencing to detect more fusions and splice variants compared to DNA-only tests.2-5 Precise Tumor is validated to 98.91% analytical sensitivity and >99.99% analytical specificity.1
Affordable
Transparent pricing with personalized cost estimates, financial assistance, and other affordability options including direct pay.
Clinical resources
References:
- Conroy JM, Pabla S, Glenn ST, et al. A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors. PLoS One. 2021;16(12):e0260089.
- Benayed R, Offin M, Mullaney K, et al. High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration as detected by DNA sequencing and low tumor mutation burden. Clin Cancer Res. 2019;25(15):4712-4722.
- Wong W, Butaney M, Schneider J, et al. Methods for identifying patients with tropomyosin receptor kinase (TRK) fusions. Pathol Oncol Res. 2020;26(3):1385-1399.
- Yang Y, Qin G, Li Y, et al. A performance comparison of commonly used assays to detect RET fusions. Clin Cancer Res. 2020;26(24):6547-6556.
- Radonic T, Geurts-Giele WRR, Samsom KG, et al. RET FISH analysis is a sensitive but highly unspecific method for RET fusions in lung cancer. J Thorac Oncol. 2021;16(2):258-265.
Myriad Genetics, MyRisk, Precise Tumor, MyChoice, Prolaris, BRACAnalysis CDx, RiskScore, and their respective logos, are registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions. EndoPredict and the EndoPredict logo are either trademarks or registered trademarks of Eurobio Scientific.
